-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, IcK8+9CvnJj1wh3U2B/irxUFfXC4Dj8Ut85RKVXUvbK1TcsZNBUhGb7xuhRtruIy V+cGtnxsqP00137iiSz7FQ== 0000893220-06-002683.txt : 20061221 0000893220-06-002683.hdr.sgml : 20061221 20061221152141 ACCESSION NUMBER: 0000893220-06-002683 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20061221 DATE AS OF CHANGE: 20061221 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: EPIX Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001027702 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 043030815 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-52847 FILM NUMBER: 061293019 BUSINESS ADDRESS: STREET 1: 4 MAGUIRE ROAD CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 6172506000 MAIL ADDRESS: STREET 1: 4 MAGUIRE ROAD CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: EPIX MEDICAL INC DATE OF NAME CHANGE: 19961129 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: GLAXOSMITHKLINE PLC CENTRAL INDEX KEY: 0001131399 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 980 GREAT WEST ROAD CITY: BRENTFORD MIDDLESEX STATE: X0 ZIP: TW8 9GS BUSINESS PHONE: 011442080475000 MAIL ADDRESS: STREET 1: 980 GREAT WEST ROAD CITY: BRENTFORD MIDDLESEX STATE: X0 ZIP: TW8 9GS SC 13G 1 w28251sc13g.txt SCHEDULE 13G EPIX PHARMACEUTICALS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* EPIX Pharmaceuticals, Inc. ------------------------------------------------------------- (Name of Issuer) Common Stock ------------------------------------------------------------- (Title of Class of Securities) 26881Q 30 9 ------------------------------------------------------------- (CUSIP Number) December 18, 2006 ------------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the following box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) x Rule 13d-1(d) *The remainder of this cover page shall be filled our for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). (Continued on following page(s)) CUSIP NO. 13G 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON GlaxoSmithKline plc 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) [ ] (b) [ ] 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION England and Wales 5 SOLE VOTING POWER NUMBER OF 4,266,795 SHARES BENEFICIALLY 6 SHARED VOTING POWER OWNED BY -0- EACH REPORTING 7 SOLE DISPOSITIVE POWER PERSON 4,266,795 WITH 8 SHARED DISPOSITIVE POWER -0- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,266,795 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ] 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 13.3% 12 TYPE OF REPORTING PERSON* CO *SEE INSTRUCTION BEFORE FILLING OUT! CUSIP NO. 26881Q 30 9 13G Item 1. (a). Name of Issuer: EPIX Pharmaceuticals, Inc. (b). Address of Issuer's Principal Executive Offices: 4 Maguire Road Lexington, MA 02421 Item 2. (a). Names of Person Filing: GlaxoSmithKline plc (b). Address of Principal Business Office: 980 Great West Road Brentford Middlesex TW8 9GS ENGLAND (c). Citizenship: England and Wales (d). Title of Class of Securities: Common stock. (e). CUSIP Number: 26881Q 30 9 Item 3. Not Applicable. Item 4. Ownership. The information in items 1 and 5 through 11 on the cover pages (page 2) on Schedule 13G is hereby incorporated by reference. Item 5. Ownership of Five Percent or Less of a Class: If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ]. Item 6. Ownership of More Than Five Percent on Behalf of Another Person: Shares held by following wholly-owned subsidiaries of Reporting Person: Glaxo Group Limited 1,629,689 SmithKline Beecham Corporation 1,379,338 S.R. One, Limited 1,257,768 Item 7. Identification and Classification of Subsidiaries Which Acquired the Security Being Reported on by the Parent Holding Company: Not applicable. Item 8. Identification and Classification of Members of the Group: Not applicable. Item 9. Notice of Dissolution of Group: Not applicable Item 10. Certification: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purpose or effect. Signature: After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. GLAXOSMITHKLINE PLC By: /s/ Victoria A. Whyte ------------------------------- Victoria A. Whyte Deputy Secretary Dated: December 21, 2006 -----END PRIVACY-ENHANCED MESSAGE-----